Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of caspofungin against Aspergillus terreus.

Literature DB >> 16304185

Efficacy of caspofungin against Aspergillus terreus.

Francesco Barchiesi¹, Elisabetta Spreghini, Alfredo Santinelli, Annette W Fothergill, Stefania Fallani, Esther Manso, Eleonora Pisa, Daniele Giannini, Andrea Novelli, Maria I Cassetta, Teresita Mazzei, Michael G Rinaldi, Giorgio Scalise.

Abstract

We investigated the in vitro and in vivo activities of caspofungin against Aspergillus terreus. The drug increased survival and reduced tissue fungal burden in neutropenic mice. Therefore, our data support the role of caspofungin in treating systemic infections due to this emerging pathogen.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2005 PMID： 16304185 PMCID： PMC1315968 DOI： 10.1128/AAC.49.12.5133-5135.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

Review 1. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors: William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal: Antimicrob Agents Chemother Date: 2004-09 Impact factor: 5.191

2. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Authors: Johan Maertens; Issam Raad; George Petrikkos; Marc Boogaerts; Dominik Selleslag; Finn B Petersen; Carole A Sable; Nicholas A Kartsonis; Angela Ngai; Arlene Taylor; Thomas F Patterson; David W Denning; Thomas J Walsh
Journal: Clin Infect Dis Date: 2004-11-09 Impact factor: 9.079

Review 3. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature.

Authors: P C Iwen; M E Rupp; A N Langnas; E C Reed; S H Hinrichs
Journal: Clin Infect Dis Date: 1998-05 Impact factor: 9.079

4. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors: R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal: Antimicrob Agents Chemother Date: 1997-11 Impact factor: 5.191

5. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

Authors: D A Sutton; S E Sanche; S G Revankar; A W Fothergill; M G Rinaldi
Journal: J Clin Microbiol Date: 1999-07 Impact factor: 5.948

Review 6. Aspergillus fumigatus and aspergillosis.

Authors: J P Latgé
Journal: Clin Microbiol Rev Date: 1999-04 Impact factor: 26.132

7. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors: S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191

8. Antifungal therapy of murine Aspergillus terreus infection.

Authors: John R Graybill; Steve Hernandez; Rosie Bocanegra; Laura K Najvar
Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191

9. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

Authors: Thomas J Walsh; Vidmantas Petraitis; Ruta Petraitiene; Aida Field-Ridley; Deanna Sutton; Mahmoud Ghannoum; Tin Sein; Robert Schaufele; Joanne Peter; John Bacher; Heather Casler; Derek Armstrong; Anna Espinel-Ingroff; Michael G Rinaldi; Caron A Lyman
Journal: J Infect Dis Date: 2003-07-09 Impact factor: 5.226

Efficacy of caspofungin against Aspergillus terreus.

Review 1. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

2. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Review 3. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature.

4. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

5. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

Review 6. Aspergillus fumigatus and aspergillosis.

7. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

8. Antifungal therapy of murine Aspergillus terreus infection.

9. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

10. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.

1. Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.

2. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.

3. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.

Review 4. Changing epidemiology of rare mould infections: implications for therapy.

5. Spondylodiscitis Due to Aspergillus terreus in an Immunocompetent Host: Case Report and Literature Review.